Dysregulation of brain reward systems in obesity: measuring endogenous dopamine levels by acute dopamine depletion - Endogenous dopamine levels in the brain in obesity

Academisch Medisch Centrum0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•* Age 18-45 years;
•* BMI >35 of 18-25 kg/m2;
•* Caucasian;
•* Able to provide written informed consent and to comply with all study procedures.

•* Currently dependent on any substance including nicotine or cannabis;
•* Diabetes mellitus and/or dyslipidemia;
•* Hypertension necessitating more than one type of medication;
•* Severe neurological or psychiatric disorders (e.g., depression, psychosis, bipolar illness, dementia, or any diseases that require psychotropic medications);
•* Serious medical illnesses;
•* Drugs known to influence binding to D2R, including neuroleptics, and methylphenidate;
•* Clinically significant abnormal laboratory values;
•* Any disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication;
•* Pregnancy or breastfeeding;
•* Contraindications for MRI scan (claustrofobia, inclusion of metal components in the body, e.g. pacemaker)
•* Measurements crossing maximum weight and size criteria for MRI and SPECT scanner.

发起方